Close Menu

NEW YORK – Recent changes to the federal Stark Law and Anti-Kickback Statute provide certain clarifications that could prove somewhat helpful to labs, but the reforms leave the industry on the outside looking in when it comes to participating in value-based care.

Some observers suggest that this could hamper efforts within the laboratory business to better leverage lab test data to impact patient health at the system and population level, a growing trend within the industry commonly referred to as Clinical Laboratory 2.0.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.